Questions: Enhancers and Long-Range Chromatin Interactions

Question 1

A mutation is found in a regulatory sequence 800 kb from a developmental gene. The mutation causes limb defects but no other abnormalities, even though the gene is expressed in many tissues. The most likely explanation is:

• A. The mutation disrupts a limb-specific splice variant in the gene's coding sequence
• B. The mutation disables a tissue-specific enhancer that drives expression only in the developing limb, while other enhancers for the same gene remain functional
• C. The long-range mutation disrupts chromatin packaging genome-wide, silencing the gene in all tissues
• D. The mutation affects the promoter through long-range DNA sequence effects specific to limb cells

Answer: (B)

A gene can have multiple enhancers, each independently driving expression in a specific tissue or developmental stage. A mutation that disables only the limb-specific enhancer causes limb defects while leaving all other expression patterns intact — the other enhancers continue to function normally. The tissue-specificity of the phenotype, combined with the distant location of the mutation, is the hallmark of an enhancer mutation. This mirrors the ZRS enhancer of sonic hedgehog, located nearly 1 Mb away, where mutations cause limb malformations without affecting Shh expression elsewhere.

Question 2

What is the role of cohesin in enhancer-promoter communication?

• A. It acts as a transcription factor that activates the target promoter directly
• B. It methylates histone H3K27ac, marking the enhancer as transcriptionally active
• C. It forms a ring structure that holds the chromatin loop together, maintaining physical contact between the enhancer and its target promoter
• D. It recruits RNA polymerase II to the enhancer to initiate transcription at that site

Answer: (C)

Cohesin is a ring-shaped protein complex that extrudes and stabilizes chromatin loops, holding the DNA loop in place and maintaining physical proximity between enhancer and promoter. This proximity allows the Mediator complex to bridge transcription factors at the enhancer with RNA polymerase II at the promoter. CTCF marks loop boundaries. Cohesin is a structural molecule enabling three-dimensional genome organization — it does not activate promoters directly, methylate histones, or initiate transcription.

Question 3

Enhancers should be located upstream of the gene they regulate and on the same DNA strand, because they need to be read by the same RNA polymerase that transcribes the gene.

• T. True
• F. False

Answer: False

Enhancers have none of these positional requirements. They can be upstream, downstream, within introns of the target gene, within introns of nearby genes, on either DNA strand, and up to 1 Mb away. Enhancers communicate with promoters through three-dimensional chromatin looping — physical proximity in nuclear space, not linear proximity on the chromosome. The stretch of DNA between enhancer and promoter loops out, and the Mediator complex bridges the two regulatory elements regardless of their linear arrangement.

Question 4

The tissue-specific activity of an enhancer is largely determined by which lineage-specific transcription factors are expressed in a given cell type and able to bind the enhancer's regulatory sequences.

• T. True
• F. False

Answer: True

Enhancers contain binding sites for multiple transcription factors. Whether an enhancer is active in a given cell type depends on which transcription factors are present to occupy those sites. Lineage-determining (pioneer) transcription factors expressed in specific cell types bind their cognate enhancer sequences, recruit coactivators and chromatin-remodeling enzymes, open the local chromatin, and facilitate loop formation. The same enhancer sequence is inactive in cells that lack the required transcription factors, which is why a gene can be expressed in some tissues and silent in others despite having the same DNA sequence everywhere.

Question 5

How does the modular organization of enhancers — one gene controlled by multiple enhancers each active in different tissues — create opportunities for evolutionary change in body plans without altering protein sequences?

Model answer: Each enhancer independently drives expression of the same gene in a specific tissue or developmental context. Evolution can mutate or disable one enhancer without affecting the others, changing the gene's expression pattern in one tissue while leaving all other functions intact. Conversely, a single nucleotide change can create a new transcription factor binding site in an enhancer, turning expression on in a new context. Because the protein sequence is not changed — only when and where it is produced — this is a low-risk route to morphological change: it does not risk disrupting protein function in the many other contexts where the gene already works. Morphological evolution driven by enhancer changes rather than coding changes helps explain why proteins are often highly conserved across species that look very different.

This modularity is a key principle in evolutionary developmental biology (evo-devo). The classic example is the repeated, independent evolution of eye loss in cave fish — achieved by mutations in a sonic hedgehog enhancer active in eye tissue, without affecting the protein used everywhere else in the body.